Dr. Powles on pivotal enfortumab vedotin data in bladder cancer

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses findings from the pivotal EV-301 trial of enfortumab vedotin (Padcev). Based on findings from the EV-301 trial and the EV-201 trial, the FDA recently granted the antibody-drug conjugate a standard approval for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy; or patients who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.